StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Piper Sandler reissued an overweight rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th.

InspireMD Stock Up 0.9 %

Shares of InspireMD stock opened at $2.61 on Wednesday. The firm has a market capitalization of $65.15 million, a P/E ratio of -3.44 and a beta of 0.91. The company has a 50 day moving average price of $2.76 and a 200 day moving average price of $2.54. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.85.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same period in the previous year, the business earned ($0.24) earnings per share. As a group, research analysts anticipate that InspireMD will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. grew its position in shares of InspireMD, Inc. (NYSE:NSPR) by 266.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the quarter. InspireMD makes up about 4.6% of Rosalind Advisors Inc.’s portfolio, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 at the end of the most recent reporting period. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.